A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
ClinicalTrials.gov · NCT00734097 · Registry updated: 2012-10-10
- Condition / research focus
- Gastroesophageal Reflux Disease
- Sponsor
- AstraZeneca
- Countries with listed sites
- Argentina · Chile · Colombia · Venezuela
- Registry dates and results
- Start: 2007-11. Completion: 2008-10 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Esomeprazole 40 mg (drug) — also listed as: Nexium
- Physical Exam (procedure)
- Quality of Life Questionnaires (other)
- pregnancy test, if applicable (procedure)
Where the study takes place — 10 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.